# US 5,707,663 A · Sustained antiepileptic therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,707,663 A
- Document ID: US5707663A
- Status: Granted
- Kind: A
- Application number: 08/442,425
- Filed: 1995-05-16
- Granted: 1998-01-13
- Earliest claimed: 1993-05-28
- Assignees: Alza Corporation
- Inventors: Atul Devatt Ayer; Richard L.-C. Yieh; Brenda J. Pollock; Patrick S.-L. Wong
- Web page: https://patentgrep.com/patent/US5707663A

## CPC

- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 9/0004: {Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas}
- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 9/1641: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/5047: {Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention pertains to a dosage form for the management of epilepsies wherein the dosage form comprises administering valproic acid or a valproic acid derivative at a continuous rate over an extended time.

## Claims

### Claim 1

A dosage form for delivering a drug to an environment of use, wherein the dosage form comprises:
(a) a semipermeable wall that surrounds a therapeutic composition comprising 10 nanograms to 750 milligrams of an antiepileptic drug selected from the group consisting of valproic acid, valproic and salts, sodium valproate, potassium valproate, calcium valproate, valpromide, valproic ester, divalproex sodium, oligomer salt of valproic acid, prodrugs of valproic acid, and pharmaceutically acceptable derivations of valproic acid, and a member selected from the group consisting of a poly(alkylene oxide) and a carboxymethylcellulose, which composition is coated with a member selected from the group consisting of a hydroxyalkylcellulose and a hydroxypropylalkylcellulose;
(b) a displacement composition surrounded by the wall for pushing the therapeutic composition from the dosage form;
(c) en exit in the dosage form for delivering the therapeutic composition from the dosage form; and wherein the;
(d) antiepileptic drug is delivered from the dosage form in a therapeutically responsive dose over an extended period of time.

### Claim 2

A dosage form for delivering a drug to an environment of use, wherein the dosage form comprises:
(a) a semipermeable wall that surrounds a therapeutic composition comprising 10 nanograms to 750 milligrams of a drug selected from the group consisting of one to three moles of valproic acid and one to six moles of a salt of valproic acid; an oligomer of valproic acid salt and valproic acid containing four moieties of the salt and the acid; three moles of valproic acid and calcium valproate; valproic acid and sodium valproate; valproic acid and divalproex sodium; and calcium valproate and valpromide; and a member selected from the group consisting of poly(alkylene oxide) and carboxymethylcellulose, which composition is coated by a member selected from the group consisting of a hydroxyalkylcellulose and hydroxypropylalkylcellulose;
(b) a displacement composition in the dosage form and surrounded by the wall, which displacement composition pushes the therapeutic composition from the dosage form;
(c) an exit in the dosage form for delivering the therapeutic composition from the dosage form; and wherein the;
(d) antiepileptic drug is delivered from the dosage form, in a therapeutically responsive dose over an extended time.